We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
BASFY's New GMP Site Set Up to Innovate Through Customer Collaboration
Read MoreHide Full Article
Key Takeaways
BASFY launched a GMP Solution Center in Michigan to supply bioprocessing ingredients reliably.
The facility features clean room packaging and advanced testing to meet evolving biopharma needs.
BASFY aims to drive innovation by closely collaborating with customers to tailor product development.
BASF SE (BASFY - Free Report) , in alignment with its commitment to providing innovative solutions in the biopharma and pharmaceutical ingredients industries, has launched a new Good Manufacturing Practice (“GMP”) Solution Center in Wyandotte, MI. It will make the supply of bioprocessing ingredients and excipients for biopharma applications reliable.
The state-of-the-art facility ensures high quality standards, clean room packaging and high-sensitivity analytical testing to help BASF expand its existing network of GMP sites in close collaboration with consumers to customize product development. These sites will harness innovation to address dynamic needs in biopharma and pharmaceutical industries. Installed with improved capabilities, BASFY will be able to regulate parameters more tightly and validate control systems for higher productivity.
The initiative underscores BASF’s drive for excellence through innovation and unique products. It highlights the company’s ability to adapt with respect to ever-changing customer needs. The GMP site would play a key role in collaboration with customers worldwide.
BASFY stock is up 0.3% over the past year against the industry’s 23.2% decline.
The Zacks Consensus Estimate for Akzo Nobel’s current-year earnings is pegged at $1.67 per share, implying a 19.3% year-over-year increase. Its earnings beat the Zacks Consensus Estimate in three of the trailing four quarters while missing once.
The Zacks Consensus Estimate for NEM’s current-year earnings is pegged at $4.18 per share, indicating a 20.1% year-over-year rise.Its earnings beat the Zacks Consensus Estimate in three of the trailing four quarters and missed once, with an average surprise of 32.41%. NEM’s shares have gained 39.6% in the past year.
The Zacks Consensus Estimate for BCPC’s 2025 earnings is pegged at $5.15 per share, indicating a rise of 31% from year-ago levels. The company’s earnings beat the consensus estimate in two of the trailing four quarters while missing the rest. Its shares have gained 3.5% in the past year.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
BASFY's New GMP Site Set Up to Innovate Through Customer Collaboration
Key Takeaways
BASF SE (BASFY - Free Report) , in alignment with its commitment to providing innovative solutions in the biopharma and pharmaceutical ingredients industries, has launched a new Good Manufacturing Practice (“GMP”) Solution Center in Wyandotte, MI. It will make the supply of bioprocessing ingredients and excipients for biopharma applications reliable.
The state-of-the-art facility ensures high quality standards, clean room packaging and high-sensitivity analytical testing to help BASF expand its existing network of GMP sites in close collaboration with consumers to customize product development. These sites will harness innovation to address dynamic needs in biopharma and pharmaceutical industries. Installed with improved capabilities, BASFY will be able to regulate parameters more tightly and validate control systems for higher productivity.
The initiative underscores BASF’s drive for excellence through innovation and unique products. It highlights the company’s ability to adapt with respect to ever-changing customer needs. The GMP site would play a key role in collaboration with customers worldwide.
BASFY stock is up 0.3% over the past year against the industry’s 23.2% decline.
Image Source: Zacks Investment Research
BASFY’s Zacks Rank & Key Picks
BASFY currently carries a Zacks Rank #3 (Hold).
Some better-ranked stocks in the Basic Materials space are Akzo Nobel N.V. (AKZOY - Free Report) , Newmont Corporation (NEM - Free Report) and Balchem Corporation (BCPC - Free Report) . While AKZOY and NEM currently sport a Zacks Rank #1 (Strong Buy) each, BCPC carries a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
The Zacks Consensus Estimate for Akzo Nobel’s current-year earnings is pegged at $1.67 per share, implying a 19.3% year-over-year increase. Its earnings beat the Zacks Consensus Estimate in three of the trailing four quarters while missing once.
The Zacks Consensus Estimate for NEM’s current-year earnings is pegged at $4.18 per share, indicating a 20.1% year-over-year rise.Its earnings beat the Zacks Consensus Estimate in three of the trailing four quarters and missed once, with an average surprise of 32.41%. NEM’s shares have gained 39.6% in the past year.
The Zacks Consensus Estimate for BCPC’s 2025 earnings is pegged at $5.15 per share, indicating a rise of 31% from year-ago levels. The company’s earnings beat the consensus estimate in two of the trailing four quarters while missing the rest. Its shares have gained 3.5% in the past year.